๐
ChondroCelect
characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins
Cartilage Diseases
๐ซ Withdrawn
Advanced therapy
โ
No active alerts
This medicine has no ongoing shortages, safety letters or recalls.
What it's used for
Repair of single symptomatic cartilage defects of the femoral condyle of the knee (International Cartilage Repair Society [ICRS] grade III or IV) in adults. Concomitant asymptomatic cartilage lesions (ICRS grade I or II) might be present. Demonstration of efficacy is based on a randomised controlled trial evaluating the efficacy of Chondrocelect in patients with lesions between 1 and 5 cmยฒ.
โ ๏ธ Patient safety
No
Official EMA page
https://www.ema.europa.eu/en/medicines/human/EPAR/chondrocelect